Revvity announced on Monday that it now expects its full-year 2025 adjusted earnings per share to exceed the upper end of its prior guidance range of $4.90 to $5.00. The upgrade reflects stronger-than-anticipated demand for its contract research and diagnostics services, particularly in translational multi-omics and biomarker identification. Management highlighted that this upward revision is driven by higher utilization rates in North America and Europe, where service volumes increased by double digits in the fourth quarter, and by improved operating leverage following recent investments in high-throughput screening platforms.

Revvity provided preliminary financial results for the fourth quarter and full year 2025 ahead of its February 2 earnings release. Fourth quarter reported revenue is expected to be approximately $772 million, up 6% year-over-year, with organic growth of 4% after adjusting for currency and acquisitions. Full year 2025 revenue is projected at roughly $2.855 billion, representing 4% reported growth and 3% organic growth versus 2024. The company will release final results before market open on Monday, February 2, 2026, and host a conference call at 8:00 a.m. ET featuring CEO Prahlad Singh and CFO Max Krakowiak. A live webcast will be available on the Investors section of Revvity's website.

Revvity has entered into a strategic collaboration with Eli Lilly to integrate its TuneLab AI drug-discovery models into Lilly’s Signals Xynthetica platform. Under the agreement, TuneLab’s federated learning technology will be deployed across Lilly’s global discovery network to enable secure, privacy-preserving data sharing and accelerate target identification. The initiative aims to unlock novel therapeutic hypotheses by combining Revvity’s expertise in bioinformatics and multi-omics with Lilly’s compound libraries and disease-model datasets, potentially reducing early-stage discovery timelines by up to 30%.